Welcome to our dedicated page for Genenta Science Spa news (Ticker: GNTA), a resource for investors and traders seeking the latest updates and insights on Genenta Science Spa stock.
Genenta Science Spa (GNTA) is a clinical-stage biotechnology pioneer developing gene therapies that reprogram immune cells to target solid tumors. This news hub provides investors and researchers with essential updates on the company's scientific advancements and strategic developments.
Access real-time information on clinical trial progress, regulatory milestones, and partnership announcements. Our curated collection includes press releases covering therapeutic innovations like Temferon for glioblastoma, TEMs-based delivery systems, and hematopoetic stem cell research breakthroughs.
Key updates focus on precision oncology developments, including trial data publications, intellectual property expansions, and collaborative research initiatives. Track the company's progress in creating localized cancer therapies through controlled interferon expression and microrna-mediated gene regulation.
Bookmark this page for streamlined access to verified GNTA updates, financial disclosures, and analysis of their novel immuno-gene therapy platform. Stay informed about developments at the intersection of gene editing and cancer immunotherapy through our maintained news repository.
Genenta Science (Nasdaq: GNTA) announced a registered direct offering to sell 4,285,715 ADSs at $3.50 per ADS for gross proceeds of approximately $15.0 million, before fees and expenses. Maxim Group is lead placement agent and Rodman & Renshaw is co-placement agent. Genenta intends to use net proceeds for working capital and general corporate purposes. The offering is expected to close on or about October 28, 2025, subject to customary closing conditions and a prospectus supplement to be filed under its effective Form F-3 registration.
Genenta Science (Nasdaq: GNTA) and ANEMOCYTE announced an expanded strategic collaboration on an off-the-shelf lentiviral vector (LVV) Plasmid DNA technology platform, dated October 24, 2025. The agreement builds on an existing partnership and makes Genenta's clinically validated LVV Plasmid DNA platform, originating from research by Professor Luigi Naldini, available to ANEMOCYTE and its clients.
The collaboration aims to supply top-quality plasmid DNA across R&D to GMP grade and from preclinical to commercial stages, supporting scalable advanced therapy program development and broadening ANEMOCYTE's offering to customers.
Genenta Science (Nasdaq: GNTA) has reported promising long-term follow-up data from its TEM-GBM study of Temferon in glioblastoma multiforme patients. The study enrolled 38 patients, with 25 receiving Temferon. Two significant milestones were achieved with two patients surviving three years from initial surgery in the TEM-LT long-term follow-up study.
Key clinical outcomes include a 29% two-year survival rate for unmethylated MGMT patients, with median overall survival at 17 months, comparing favorably to historical cohorts showing approximately 14% two-year survival and 13-15 months median survival with standard care.
The company has also initiated the TEM-GU Phase 1 study for genitourinary tumors, targeting 12 patients with Metastatic Renal Cell Carcinoma. The trial will evaluate Temferon's combination potential with immune checkpoint inhibitors or tyrosine kinase inhibitors. Additionally, a scientific manuscript demonstrating Temferon's potential in enhancing CAR-T activity has been accepted for publication in Science Translational Medicine.
Genenta Science (NASDAQ: GNTA) has announced its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City. The company's Chief Medical Officer, Carlo Russo, will be available for one-on-one meetings from 9:00 A.M. to 3:00 P.M. (ET). Interested parties can schedule meetings by contacting John Perez at jperez@dboralcapital.com.
Genenta Science (GNTA) has announced a strategic collaboration with Anemocyte, an Italian Biotech Manufacturing Organization (BMO), for the production of critical starting materials for cell-based therapies. The partnership involves the successful establishment of Cell Banks and manufacturing of Plasmids for viral vector production. Anemocyte's expertise has been crucial in supporting Genenta's clinical trials progression through high-quality manufacturing processes. The collaboration highlights the synergy between Genenta's immuno-oncology platform and Anemocyte's manufacturing capabilities, with Genenta being notably recognized as the first Italian company listed on Nasdaq.
Genenta Science (Nasdaq: GNTA) announced its upcoming presentation at the 'Montalcini Global Biotech Tour' in Doha, Qatar on April 17th, 2025. The presentation follows two significant financial developments:
1. A €20 million ($22.7 million) strategic financing through a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB), aimed at advancing Temferon™ in metastatic Renal Cell Cancer (mRCC)
2. An additional €3.0 million ($3.2 million) raised via an at-the-market (ATM) facility
The event will be hosted by Qatar's Minister of State for Foreign Trade Affairs and Italy's Minister of Health, featuring presentations from key stakeholders including Qatar Research, Development and Innovation Council (QRDI) and potential meetings with Qatar Investment Authority (QIA), which manages over $475 billion in assets.
Genenta Science (GNTA) has secured a €20 million ($21.9M) financing through a Mandatory Convertible Bond from ENEA Tech and Biomedical (ETB) to expand its pipeline. The funding will support advancing Temferon in metastatic Renal Cell Cancer (mRCC).
The bond structure includes a first tranche of €7.5M for safety assessment in the mRCC trial, and a second tranche of €12.5M conditional upon achieving safety milestones. The bond matures in March 2028 with a two-year lock-up period, and ETB's equity will be capped at 29% with a maximum conversion price of $17.64 per share.
Recent data from the Phase 1/2a Glioblastoma Multiforme (GBM) uMGMT trial shows promising results with 29% patient survival at two years (up from 25% in October) and 17 months median overall survival, compared to historical data of 14% two-year survival and 13-15 months median survival with standard care.
The Italian Trade Agency (ITA) hosted the eighth edition of 'Italy on the Move' during the 43rd J.P. Morgan Healthcare Conference 2025, attracting over 230 executives and investors. The event highlighted investment opportunities in Italy's €270 Billion life sciences sector. Director General Mauro Battocchi presented Italy's achievements, including €2 billion in pharma R&D investments in 2023 and an average life expectancy of 83.8 years.
The event featured a panel discussion titled 'Navigating Transatlantic Partnerships in Life Sciences,' moderated by Audrey Greenberg, with participation from prominent executives including leaders from Rubedo Life Sciences, Bracco Imaging, Menarini Group, TPG Capital, Genenta Science, ENEA Tech and Biomedical, and DOC Pharma. Five Italian startups also pitched their innovations: Aavantgarde, Butterfly Decisions, Cellply, Medlea, and Sibylla Biotech.
Italy on the Move, a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025, will showcase Italy as a leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals. The event, hosted by The Italian Trade Agency and the Ministry of Foreign Affairs, will take place on January 15th, 2025, at INNOVIT in San Francisco.
The event will feature notable speakers including Italian Ambassador H.E. Mariangela Zappia and include a panel discussion on Transatlantic Partnerships in Life Sciences. Five Italian startups - Aavantgarde, Butterfly Decisions, Cellply, Medlea, and Sibylla Biotech - will present pitch presentations. The event highlights Italy's €270 Billion life sciences sector and aims to foster innovation and collaboration between Italian and American stakeholders.
Genenta Science (NASDAQ: GNTA) has enhanced its partnership with AGC Biologics by securing an exclusive GMP manufacturing suite at AGC's Cell and Gene Center of Excellence in Milan. This strategic amendment aims to strengthen the production of Genenta's cell therapy products, ensuring cGMP compliance.
The company's metastatic Renal Cell Cancer (mRCC) Phase 1/2a trial, initiated in Q4 2024, aims to treat six patients by H1 2025, while the Glioblastoma Multiforme (GBM) study continues. Genenta plans to manufacture 27 autologous drug products in 2025.
Recent preclinical and clinical studies highlight Temferon's capability to reprogram the tumor microenvironment, inhibit myeloid cell-induced immune suppression, and enhance T-cell responses. The company suggests potential synergies with immunotherapeutic strategies, including immune checkpoint inhibitors and CAR-T cell therapies.
FAQ
What is the current stock price of Genenta Science Spa (GNTA)?
What is the market cap of Genenta Science Spa (GNTA)?
